Non-high-density lipoprotein cholesterol: An important predictor of stroke and diabetes-related mortality in Japanese elderly diabetic patients

Geriatrics and Gerontology International

Volumn 12, Issue SUPPL.1, 2012, Pages 18-28

  Araki, Atsushi ^a   Iimuro, Satoshi ^b   Sakurai, Takashi ^f,g   Umegaki, Hiroyuki ^h   Iijima, Katsuya ^b,c   Nakano, Hiroshi ^d   Oba, Kenzo ^d   Yokono, Koichi ^f   Sone, Hirohito ⁱ   Yamada, Nobuhiro ⁱ   Ako, Junya ^c   Kozaki, Koichi ^c   Miura, Hisayuki ^g   Kashiwagi, Atsunori ^j   Kikkawa, Ryuichi ^j   Yoshimura, Yukio ^k   Nakano, Tadasumi ^e   Ohashi, Yasuo ^b   Ito, Hideki ^a  

^a Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d NIPPON MEDICAL SCHOOL   (Japan)

^e Tokyo Metropolitan Tama Geriatric Hospital   (Japan)

^f KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^h NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ UNIVERSITY OF TSUKUBA   (Japan)

^j SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^k SHIKOKU UNIVERSITY   (Japan)

more..

Author keywords

Diabetes mellitus; Diabetic complications; Elderly; Non high density lipoprotein cholesterol; Stroke

Indexed keywords

CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NON HIGH DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; FEMALE; GERIATRIC PATIENT; HUMAN; ISCHEMIC HEART DISEASE; JAPAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; SURVIVAL RATE; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; LIPOPROTEINS; MALE; RISK FACTORS; STROKE;

EID: 84858761181     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2011.00809.x     Document Type: Article

References (36)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
3. Ohkubo Y, Kishikawa H, Araki E etal. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
4. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
5. Gerstein HC, Miller ME, Byington RP etal. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
6. Duckworth W, Abraira C, Moritz T etal. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-139.
7. Pop-Busui R, Evans GW, Gerstein HC etal. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Diabetes Care 2010; 33: 1578-1584.
8. Bittner V. Non-high-density lipoprotein cholesterol: an alternate target for lipid-lowering therapy. Prev Cardiol 2004; 7: 122-126.
9. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P etal. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993-2000.
10. Kurth T, Everett BM, Buring JE, Kase CS, Ridker PM, Gaziano JM. Lipid levels and the risk of ischemic stroke in women. Neurology 2007; 68: 556-562.
11. Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 2009; 29: 424-430.
12. Bittner V, Hardison R, Kelsey SF, Weiner BH, Jacobs AK, Sopko G, Bypass Angioplasty Revascularization Investigation. Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 2002; 106: 2537-2342.
13. Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH, EURODIAB Prospective Complications Study Group. Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care 2008; 31: 1360-1366.
14. Nishizawa Y, Shoji T, Kakiya R etal. Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int Suppl 2003; 84: S117-S120.
15. Herman MP, Sacks FM, Ahn SA, Rousseau MF. Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: discriminant ratio and unbiased equivalence. Cardiovasc Diabetol 2011; 10: 20.
16. Cui Y, Blumenthal RS, Flaws JA etal. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001; 161: 1413-1419.
17. Miller M, Ginsberg HN, Schaefer EJ. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol 2008; 101: 1003-1008.
18. Tanabe N, Iso H, Okada K etal. Japan Arteriosclerosis Longitudinal Study Group. Serum total and non-high-density lipoprotein cholesterol and the risk prediction of cardiovascular events - the JALS-ECC. Circ J 2010; 74: 1346-1356.
19. Kitamura A, Noda H, Nakamura M etal. Association between non-high-density lipoprotein cholesterol levels and the incidence of coronary heart disease among Japanese: the Circulatory Risk in Communities Study (CIRCS). J Atheroscler Thromb 2011; 18: 454-463. Mar 3. [Epub ahead of print].
20. Bruno G, Merletti F, Biggeri A etal. Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study. Diabetologia 2006; 49: 937-944.
21. von Mühlen D, Langer RD, Barrett-Connor E. Sex and time differences in the associations of non-high-density lipoprotein cholesterol versus other lipid and lipoprotein factors in the prediction of cardiovascular death (The Rancho Bernardo Study). Am J Cardiol 2003; 91: 1311-1315.
22. Noda H, Iso H, Irie F, Sairenchi T, Ohtaka E, Ohta H. Association between non-high-density lipoprotein cholesterol concentrations and mortality from coronary heart disease among Japanese men and women: the Ibaraki Prefectural Health Study. J Atheroscler Thromb 2010; 17: 30-36.
23. Akerblom JL, Costa R, Luchsinger JA etal. Relation of plasma lipids to all-cause mortality in Caucasian, African-American and Hispanic elders. Age Ageing 2008; 37: 207-213.
24. Araki A, Iimuro S, Sakurai T etal. and the Japanese Elderly Intervention Trial Research Group: long-term multiple risk factor interventions in Japanese elderly people with diabetes mellitus: the Japanese Elderly Intervention Trial (J-EDIT): study design, baseline characteristics, and effects of intervention. Geriatr Gerontol Int 2012; 12 (Suppl. 1): 7-17.
25. Koyano W, Shibata H, Nakazato K, Haga H, Suyama Y. Measurement of competence: reliability and validity of the TMIG index of Competence. Arch Gerontol Geriatr 1991; 13: 103-116.
26. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-193.
27. Sheikh JI, Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. Clin Gerontol 1986; 5: 165-173.
28. Colhoun HM, Betteridge DJ, Durrington PN etal., the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
29. Xu K, Han YL, Jing QM etal. Lipid-modifying therapy in diabetic patients with high plasma non-high-density lipoprotein cholesterol after percutaneous coronary intervention. Exp Clin Cardiol 2007; 12: 48-50.
30. Kuusisto J, Mykkanen L, Pyorala L, Laakso M. Non-insulin dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke 1994; 25: 1157-1164.
31. Giorda CB, Avogaro A, Maggini M etal. The DAI study group. Incidence and risk factors for stroke in type 2 diabetic patients. The DAI Study. Stroke 2007; 38: 1154-1160.
32. Currie CJ, Peters JR, Tynan A etal. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375: 481-489.
33. Chrysant SG. Current status of aggressive blood pressure control. World J Cardiol 2011; 3: 65-71.
34. Sleight P, Redon J, Verdecchia P etal. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009; 27: 1360-1369.
35. Petersen LK, Christensen K, Kragstrup J. Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+ year old. Age Ageing 2010; 39: 674-680.
36. Vasudevan MM, Ballantyne CM. Advances in lipid testing and management in patients with diabetes mellitus. Endocr Pract 2009; 15: 641-652.